ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Circulating tumor DNA (ctDNA)
epidermal growth factor receptor (EGFR)
non-small-cell lung cancer (NSCLC)
osimertinib
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
18
7
2020
Statut:
ppublish
Résumé
Several clinical trials have demonstrated the efficacy and safety of osimertinib in advanced non-small-cell lung cancer (NSCLC). However, there is significant unexplained variability in treatment outcome. Observational prospective cohort of 22 pre-treated patients with stage IV NSCLC harboring the epidermal growth factor receptor ( The median progression-free survival (PFS), since the start of osimertinib, was 8.9 [interquartile range (IQR): 4.6-18.0] months. The median treatment durations of sequential gefitinib + osimertinib, afatinib + osimertinib and erlotinib + osimertinib treatments were 30.1, 24.6 and 21.1 months, respectively. The p.T790M mutation was detected in 19 (86%) pre-treatment blood samples. Undetectable levels of the original Different molecular patterns identified by plasma genotyping may be of prognostic significance, suggesting that the use of liquid biopsy is a valuable approach for tumor monitoring.
Sections du résumé
BACKGROUND
BACKGROUND
Several clinical trials have demonstrated the efficacy and safety of osimertinib in advanced non-small-cell lung cancer (NSCLC). However, there is significant unexplained variability in treatment outcome.
METHODS
METHODS
Observational prospective cohort of 22 pre-treated patients with stage IV NSCLC harboring the epidermal growth factor receptor (
RESULTS
RESULTS
The median progression-free survival (PFS), since the start of osimertinib, was 8.9 [interquartile range (IQR): 4.6-18.0] months. The median treatment durations of sequential gefitinib + osimertinib, afatinib + osimertinib and erlotinib + osimertinib treatments were 30.1, 24.6 and 21.1 months, respectively. The p.T790M mutation was detected in 19 (86%) pre-treatment blood samples. Undetectable levels of the original
CONCLUSIONS
CONCLUSIONS
Different molecular patterns identified by plasma genotyping may be of prognostic significance, suggesting that the use of liquid biopsy is a valuable approach for tumor monitoring.
Identifiants
pubmed: 32676317
doi: 10.21037/tlcr.2020.04.01
pii: tlcr-09-03-532
pmc: PMC7354150
doi:
Types de publication
Journal Article
Langues
eng
Pagination
532-540Informations de copyright
2020 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/ tlcr.2020.04.01). AR reports other from Boehringer, Takeda during the conduct of the study. VC reports other from Roche, BMS, MSD, Pfizer, Lilly, AstraZeneca, Boehringer, Novartis, Takeda during the conduct of the study. MP reports other from Roche, BMS, MSD, Pfizer, Lilly, grants and other from AstraZeneca, Boehringer, other from Novartis, Takeda during the conduct of the study. MP serves as an unpaid editorial board member of Translational Lung Cancer Research from Sep 2019 to Sep 2021. The other authors have no conflicts of interest to declare.
Références
Ann Oncol. 2015 Oct;26(10):2073-8
pubmed: 26269204
BMC Cancer. 2019 Apr 30;19(1):410
pubmed: 31039766
Oncotarget. 2017 Nov 16;9(1):488-494
pubmed: 29416630
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Clin Chem Lab Med. 2020 Jan 28;58(2):306-313
pubmed: 31469650
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Nat Commun. 2016 Jun 10;7:11815
pubmed: 27283993
N Engl J Med. 2005 Jul 14;353(2):207-8
pubmed: 16014893
Br J Cancer. 2003 Jul 21;89(2):232-8
pubmed: 12865907
JAMA Oncol. 2018 Nov 1;4(11):1527-1534
pubmed: 30073261
Oncotarget. 2017 Aug 7;8(36):60291-60298
pubmed: 28947971
JAMA Oncol. 2015 Oct;1(7):982-4
pubmed: 26181354
Nat Med. 2015 Jun;21(6):560-2
pubmed: 25939061
J Thorac Oncol. 2016 Oct;11(10):e121-3
pubmed: 27257132
Lancet. 2016 Sep 3;388(10048):1012-24
pubmed: 27598681
Future Oncol. 2019 Sep;15(26):3003-3014
pubmed: 31339357
Clin Cancer Res. 2015 May 1;21(9):2157-66
pubmed: 25623215
Ann Oncol. 2017 Sep 1;28(9):2248-2255
pubmed: 28911086
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Lung Cancer. 2017 Jun;108:228-231
pubmed: 28625641
Br J Cancer. 2018 Nov;119(10):1252-1258
pubmed: 30397287
Clin Cancer Res. 2018 Jul 1;24(13):3097-3107
pubmed: 29506987
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168